Core Laboratories (CLB) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue was $130.2 million, up 5% sequentially and flat year-over-year, with operating income of $15.3 million and GAAP EPS of $0.22.

• Net income attributable to shareholders was $10.6 million, up 18% year-over-year and a significant improvement from the prior quarter.

• Free cash flow rose to $10.4 million, up over 160% sequentially, and net debt was reduced by $9.1 million; leverage ratio improved to 1.27, the lowest in eight years.

• Strategic focus remained on technology investments, operational efficiency, and shareholder returns, with international demand strengthening, especially in the Middle East, Africa, and South America.

• Geopolitical conflicts, sanctions, and tariffs created volatility, but long-term international demand remains constructive.

Financial highlights

• Revenue for Q2 2025 was $130.2 million, up 5% sequentially and flat year-over-year; product sales rose 19% sequentially but fell 1% year-over-year.

• GAAP net income for Q2 2025 was $10.6 million, up 17.8% year-over-year; diluted EPS $0.22; EPS (excluding items) was $0.19.

• Free cash flow for Q2 2025 was $10.4 million, with cash from operations at $13.9 million and capex at $3.5 million.

• Operating margins improved: Reservoir Description at 13%, Production Enhancement at 9%.

• ROIC improved to 9.0% in Q2 2025.

Outlook and guidance

• Q3 2025 revenue projected at $127.5–$134.5 million, with operating income of $13.6–$16.2 million and EPS of $0.18–$0.22.

• Reservoir Description Q3 revenue expected at $84–$88 million; Production Enhancement forecast at $43.5–$46.5 million.

• International projects expected to remain resilient, while U.S. onshore activity is more sensitive to oil price volatility.

• Market volatility expected due to tariffs, OPEC+ production changes, and geopolitical conflicts; long-term international outlook remains positive.